Phase I Study of the Pan-Pi3k Inhibitor Buparlisib in Adult Chinese Patients With Advanced Solid Tumors

Anticancer Research - Greece
doi 10.21873/anticanres.11212
Full Text
Abstract

Available in full text

Date
Authors
Publisher

International Institute of Anticancer Research

Related search

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

A Phase I Study of NLG919 for Adult Patients With Recurrent Advanced Solid Tumors

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

A Phase 1 Study of Alpelisib (BYL719), an Α- Specific PI3K Inhibitor, in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2019English

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2006English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy